Clinical trials: Subjects With Type 2 Diabetes Mellitus.
Diabetes, Diabetes Mellitus, Type 2
Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes
This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin or rosiglitazone treatment, both in combination with metformin and glimepiride.
- Trial name
- NCT00427154
- Testing
- rosiglitazone, inhaled human insulin, metformin
- Where
- 103 sites in United States
- Volunteers
- 227 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus
Primary objective: To determine the optimal treatment algorithm for the clinical use of insulin glargine based on the incidence of severe hypoglycaemia.
- Trial name
- AT-LANTUS (NCT00399724)
- Testing
- Insulin glargine
- Volunteers
- 7,376 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide
Many patients with type 2 diabetes also have conditions that are treated with diuretics. The patients may also be treated with GSK189075 for their diabetes.
- Trial name
- NCT00671424
- Testing
- Hydrochlorothiazide (HCTZ), Remogliflozin etabonate (GSK189075), Furosemide
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 2
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate Safety and efficacy of oral semaglutide versus dulaglutide both in combination with one OAD (oral antidiabetic drug) in Japanese subjects with type 2…
- Trial name
- PIONEER 10 (NCT03015220)
- Testing
- Semaglutide, Dulaglutide
- Where
- 34 sites in Japan
- Volunteers
- 458 people
- Sponsor
- Novo Nordisk A/S
Hypertension, Diabetes Mellitus, Type 2
A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects
The purpose of this study is to evaluate the pharmacokinetic interaction and safety between BR1019-1 and BR1019-2 in healthy adult subjects.
- Trial name
- NCT05875259
- Testing
- BR1019-1, BR1019-2, BR1019-1 + BR1019-2
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
PreDiabetes, Pre Diabetes
STAR Study Investigating Performance and Safety of the Medical Device SiPore15™
The primary objective of STAR01 is to evaluate the performance and safety of the medical device (class IIb) SiPore15™ after a 12-week long treatment in the target population of obese and overweight subjects with prediabetes or…
- Conditions
- PreDiabetes, Pre Diabetes, Prediabetic State, Type2 Diabetes
- Trial name
- NCT03823027
- Testing
- SiPore15™
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 43 people
- Sponsor
- Sigrid Therapeutics AB
Type 2 Diabetes Mellitus
Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes
This study is being carried out to see if dapagliflozin in addition to metformin decreases body weight and if so, how it compares with metformin alone.
- Trial name
- NCT00855166
- Testing
- Dapagliflozin, Metformin, Sitagliptin
- Where
- 21 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 182 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Chronicare for Type 2 Diabetes (Chronicare-T2D)
This single-blind, single-center, randomized, controlled trial is designed to evaluate the utility of the Chronicare Disease Management Program in the management of subjects with T2D who are being treated with insulin glargine…
- Trial name
- CRX-T2D (NCT03997331)
- Testing
- CRx Health, Chronicare
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- QuiO
Type 2 Diabetes Mellitus
A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes
This is a bicentric, double-blinded, randomised, four-period crossover phase 1 trial, using automated 30-hour euglycemic clamp in subjects with type 2 diabetes mellitus.
- Trial name
- NCT03180710
- Testing
- BioChaperone® Combo 75/25 at 0.6 U/kg, BioChaperone® Combo 75/25 at 0.8 U/kg, BioChaperone® Combo 75/25 at 1.0 U/kg
- Where
- 2 sites in Germany
- Volunteers
- 32 people
- Sponsor
- Adocia
Diabetes Mellitus Type 2
Medium-term Effects of a Polyphenol-rich Beverage Based on Red Grape Pomace Extract on Non-alcoholic Fatty Liver Disease, Cardiometabolic Risk Profile and Gut Microbiota in Subjects with Type 2 Diabetes
Nonalcoholic fatty liver disease (NAFLD) is a liver disease characterized by an abnormal accumulation of fat not due to alcohol or drug consumption that can evolve into steatohepatitis (NASH), fibrosis and cirrhosis.
- Trial name
- PoLiFat (NCT06895018)
- Testing
- Supplementation with Polyphenol Rich Drink
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Federico II University
Type 2 Diabetes
Chronotherapy with Low-dose Aspirin for Primary Prevention
Brief summary: Aspirin (ASA) has been shown to provide marked benefits in primary and secondary prevention of cardiovascular events.
- Trial name
- CARING (NCT00725127)
- Testing
- aspirin
- Where
- 19 sites in Spain
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- University of Vigo
Hypertension, Diabetes Mellitus
Rationale and Design for Shiga Microalbuminuria Reduction Trial
The purpose of this trial are to evaluate the reduction of urinary albumin excretion by an angiotensin receptor blocker (ARB), valsartan, in comparison with a calcium channel blocker (CCB), amlodipine, in Japanese hypertensive…
- Conditions
- Hypertension, Diabetes Mellitus, Albuminuria
- Trial name
- NCT00202618
- Testing
- Valsartan, Amlodipine
- Where
- Japan
- Volunteers
- 160 people
- Sponsor
- Shiga University
Type 2 Diabetes, Obesity
Effect of Bile Acids on GLP-1 Secretion
The purpose of this study is to describe the physiological, pathophysiological and potentially therapeutic implications of bile-induced glucagon-like peptide-1 (GLP-1) secretion in human glucose homeostasis.
- Trial name
- NCT01666223
- Testing
- Colesevelam, Chenodeoxycholic Acid, saline
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes, Diabetes Mellitus, Type 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01865279
- Testing
- insulin degludec, isophane human insulin
- Where
- Germany
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study of HS-20094 in Healthy Participants
This study includes two parts (Single Ascending Dose, SAD; Multiple-Ascending Dose, MAD) and enrolls healthy participants. Participants in SAD accept single subcutaneous (SC) injection of HS-20094 and participants in MAD accept…
- Trial name
- NCT05116410
- Testing
- HS-20094
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan
This trial is conducted in Africa and Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart twice daily and biphasic insulin aspart twice daily in subjects with type 2 diabetes mellitus…
- Trial name
- NCT02648217
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart
- Where
- 32 sites in Algeria, India and 4 more
- Volunteers
- 263 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Malaysia
This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control, and complications in diabetic subjects in Asia.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare Asia (NCT00877526)
- Testing
- No treatment given
- Where
- Malaysia
- Volunteers
- 1,670 people
- Sponsor
- Novo Nordisk A/S
Xerosis Cutis
Comparison Dry Foot Skin Between Diabetic and Non-diabetic Subjects and the Effects of Two Cosmetic Foot Care Products
The overall aims of this study are to compare the structure and function of dry to very dry and cracked foot skin between diabetic and nondiabetic subjects and to evaluate the effects of two cosmetic leave-on products on dry and…
- Trial name
- NCT05046015
- Testing
- 10% Urea foot lotion, 10% Urea foot ointment
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Galderma R&D
Diabetes, Diabetes Mellitus, Type 1
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of this trial is to compare two NN1250 (insulin degludec) formulations with each other and with insulin glargine, all in combination with…
- Trial name
- NCT00612040
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 33 sites in United States, Australia and 3 more
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Neuropathy, Diabetic
Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.
Fluid management study in patients with type 2 diabetes and autonomic neuropathy.
- Trial name
- NCT00422955
- Testing
- rosiglitazone
- Where
- Netherlands
- Volunteers
- 36 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.